World's Best Scientists 2026 revealed!
Gregor Verhoef

Gregor Verhoef

D-Index & Metrics

Medicine

D-Index
91
Citations
41324
World Ranking
11572
National Ranking
139

Overview

Gregor Verhoef is affiliated with KU Leuven in Belgium and has contributed extensively to the field of Medicine, with a particular focus on oncology-related disciplines. Their research encompasses diverse subfields, including Pathology and Forensic Medicine, Genetics, Oncology, Neurology, and Hematology.

Verhoef's work often centers on lymphoma and leukemia research, addressing both diagnosis and treatment approaches. The main topics of their research include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • CAR-T cell therapy research
  • CNS Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Viral-associated cancers and disorders
  • Glioma Diagnosis and Treatment

The scientist regularly publishes in several key medical journals that focus on hematology and oncology, notably:

  • Blood
  • Leukemia & lymphoma/Leukemia and lymphoma
  • Leukemia
  • Cancer Immunology Immunotherapy
  • Journal of Clinical Oncology

Gregor Verhoef has collaborated frequently with other researchers in related fields. Notable co-authors include:

  • Daan Dierickx
  • Thomas Tousseyn
  • Peter Vandenberghe
  • Lukas Marcelis
  • Koen Debackere

Among their recent papers are important clinical and therapeutic studies, including:

  • "Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)," published in the Journal of Clinical Oncology in 2020
  • "Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma," published by Leukemia & lymphoma/Leukemia and lymphoma in 2020
  • "Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier," published in Blood in 2020
  • "Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma," published in Leukemia in 2020
  • "In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy," published in Cancer Immunology Immunotherapy in 2020

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Stromal gene signatures in large-B-cell lymphomas

    G Lenz;G Wright;S S Dave;W Xiao

  • High-dose daunorubicin in older patients with acute myeloid leukemia.

    Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten

  • Acquired mutations in TET2 are common in myelodysplastic syndromes

    Saskia M C Langemeijer;Roland P Kuiper;Marieke Berends;Ruth Knops

  • Galactomannan and Computed Tomography–Based Preemptive Antifungal Therapy in Neutropenic Patients at High Risk for Invasive Fungal Infection: A Prospective Feasibility Study

    Johan Maertens;Koen Theunissen;Gregor Verhoef;Johnny Verschakelen

  • Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients

    P Wijermans;M Lübbert;Gregor Verhoef;A Bosly

  • ALK+ Lymphoma: Clinico-Pathological Findings and Outcome

    Brunangelo Falini;Stefano Pileri;Pier Luigi Zinzani;Antonino Carbone

  • Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

    Georg Hess;Raoul Herbrecht;Jorge Romaguera;Gregor Verhoef

  • Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

    Lucien Noens;Marie Anne Van Lierde;Robrecht De Bock;Gregor Verhoef

  • Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

    Dimitri A. Breems;Wim L.J. Van Putten;Peter C. Huijgens;Gert J. Ossenkoppele

  • Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis

    Johan Maertens;Jan Verhaegen;Hilde Demuynck;Penelope Brock

  • Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma

    K. Spaepen;S. Stroobants;P. Dupont;P. Vandenberghe

  • Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18f]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma : Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

    Karoline Spaepen;Sigrid Stroobants;Patrick Dupont;Steven Van Steenweghen

  • Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia

    Koenraad Devriendt;Annette S. Kim;Gert Mathijs;Suzanna G M Frints

  • Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

    Anjali Advani;Bertrand Coiffier;Myron S. Czuczman;Martin Dreyling

  • Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

    Tadeusz Robak;Huiqiang Huang;Jie Jin;Jun Zhu

  • High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani;Claudia Erpelinck;Wim L. J. van Putten;Peter J. M. Valk

  • An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

    Gregor Verhoef;Hans E Johnsen;Francesca Gaia Rossi;Antonio Salar

Frequent Co-Authors

Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Bob Löwenberg
Bob Löwenberg Erasmus MC
Stefania Pittaluga
Stefania Pittaluga National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens a range of opportunities beyond the traditional MD route. Online education has made it more accessible than ever to pursue diverse health-related roles. For those interested in pharmacy, pharmd online programs provide a flexible path to become a Doctor of Pharmacy, combining clinical expertise with patient care skills.

The demand for tech-savvy professionals is rising in healthcare. Pursuing a degree in health informatics prepares graduates to manage patient data, improve systems, and ensure data security. Similarly, a medical coding certification opens doors to careers in billing, coding, and healthcare administration—vital roles that keep clinics and hospitals running smoothly.

For those with a passion for patient care, there are also most affordable nurse practitioner programs available online, offering advanced clinical training and leadership development. These varied pathways enable students to join the healthcare sector in ways that best fit their interests and lifestyles.

Best Scientists Citing Gregor Verhoef

Trending Scientists

Recently Published Articles